anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sudden unexpected death in infants (SUDI) is a traumatic event for families, and unfortunately its occurrence remains high in many parts of the world. Whilst cause of death is resolved for most cases, others remain undetermined following postmortem investigations. There has been a recognition of the role of genetic testing in unexplained cases, where previous studies have demonstrated the resolution of cases through DNA analyses. Here we present two case reports of SUDI cases admitted to Salt River Mortuary, South Africa, and show that underlying causes of death were determined for both infants using clinical exome sequencing. The first infant was heterozygous for a variant (rs148175795) in COL6A3, which suggested a bronchopulmonary dysplasia phenotype. This hypothesis led to finding of a second candidate variant in DMP1 (rs142880465), which may contribute towards a digenic/polygenic mechanism of a more severe phenotype. Histological analysis of retained tissue sections showed an asphyxial mechanism of death, where bronchiolar muscle weakness from an underlying bronchopulmonary dysplasia may have contributed to the asphyxia by affecting respiration. In the second infant, a homozygous variant (rs201340753) was identified in MASP1, which was heterozygous in each parent, highlighting the value of including parental DNA in genetic studies. Whilst mannose-binding lectin deficiency could not be assessed, it is plausible that this variant may have acted in combination with other risk factors within the triple-risk model to result in sudden death. These results may have genetic implications for family members, and represent possible new candidate variants for molecular autopsies.
The invention discloses a water-phase solution of rice bran fatty alkanol and a preparation method thereof. The preparation method comprises the following steps of 1: weighing the rice bran fatty alkanol and the tween 80, mixing and heating to obtain a primary mixed base material; step 2: and adding a water phase solvent and ethanol into the primarily mixed base material, and uniformly mixing to obtain a rice bran fatty alkanol aqueous phase solution. According to the preparation method of the water phase solution of the rice bran fatty alkanol, Tween 80 is used as an emulsifier, the rice bran fatty alkanol is dissolved in the water phase solvent, the water phase solution of the rice bran fatty alkanol is in a clear, transparent and stable state, the rice bran fatty alkanol can be applied to various products using the water phase solvent as a basic solvent, and the application range of the rice bran fatty alkanol can be greatly improved. Wherein, ethanol is a cosolvent, which increases the solubility of the rice bran fatty alkanol in the aqueous phase solvent. The Tween 80 has small taste, and can make the water phase solution of rice bran fatty alkanol be in a clear, transparent and stable state, and has small smell. The ethanol is edible ethanol.
Voluntary movement and sensory perception are fundamental aspects of the human experience. Senses such as visual and proprioceptive feedback inform movement by continuously providing the central nervous system with information on limb location, movement error, and task performance. However, the specific mechanisms behind how different forms of sensory information are used to adapt and generalize movement remain poorly understood.

Motor adaptation, or the modification of movement based on error feedback (Martin et al., 1996), is often elicited during rehabilitation but must be generalized to functional performance, such as activities of daily living, in order to successfully rehabilitate motor deficits following stroke. Motor adaptation and generalization are believed to occur via the integration of various forms of sensory feedback for a congruent representation of the body's position in space along with estimation of inertial properties of the limb segments for accurate specification of movement. Thus, motor adaptation is often studied within curated environments incorporating a "mis-match" between different sensory systems (i.e. a visual field shift via prism googles or a visuomotor rotation via virtual reality environment) and observing how motor plans change based on this mis-match. However, these adaptations are environment-specific and show little generalization outside of their restricted experimental setup. There remains a need for motor adaptation research that demonstrates motor learning that generalizes to other environments and movement types. This work could then inform physical and occupational therapy neurorehabilitation interventions targeted at addressing motor deficits.
The management of acute liver failure (ALF) in modern hepatology intensive care units (ICU) has improved patient outcomes. Critical care management of hepatic encephalopathy, cerebral edema, fluid and electrolytes; prevention of infections and organ support are central to improved outcomes of ALF. In particular, the pathogenesis of encephalopathy is multifactorial, with ammonia, elevated intra-cranial pressure and systemic inflammation playing a central role. Although ALF remains associated with high mortality, the availability of supportive care, including organ failure support such as plasma exchange, timely mechanical ventilation or continuous renal replacement therapy, either conservatively manages patients with ALF or offers bridging therapy until liver transplantation. Thus, appropriate critical care management has improved the likelihood of patient recovery in ALF. ICU care interventions such as monitoring of cerebral edema, fluid status assessment and interventions for sepsis prevention, nutritional support and management of electrolytes can salvage a substantial proportion of patients. In this review, we discuss the key aspects of critical care management of ALF.
Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 17 courses after chemoradiation if no residual disease is found or for up to 35 courses after chemoradiation if residual disease is found. After 3 days, patients also receive docetaxel IV over 1 hour Q1W and doxorubicin hydrochloride IV Q1W, and undergo IMRT once daily 5 days per week for 6.5 weeks in the absence of disease progression or unacceptable toxicity.
Assigned guided imagery will be delivered during each exercise session throughout the 6-week exercise program. The guided imagery recordings will be delivered via audio recording during warm-up and cool-down periods during in-lab exercise sessions. The ERT will always be delivered during warm-up and the NAI will always be delivered during cool-down.
BACKGROUND: Postoperative gastrointestinal dysfunction (POGD) commonly occurs following gastrointestinal (GI) surgery and is associated with specific anesthetic agents. Cholinesterase inhibitors employed for reversing neuromuscular blockade have been implicated in development of POGD. Sugammadex, a novel reversal agent, is linked with reduced POGD. However, there is a lack of comprehensive comparative review between these agents regarding their impact on POGD following GI surgery. This study aims to systematically review the effects of sugammadex on POGD compared to cholinesterase inhibitors following GI surgery.
METHODS: MEDLINE, EMBASE, and CENTRAL were searched as of July 2022 to identify articles comparing sugammadex with cholinesterase inhibitors in patients undergoing gastrointestinal surgery, specifically in relation to POGD. Secondary endpoints included length of hospital stay, readmission rates, pulmonary complications, and postoperative morbidity.
RESULTS: From 198 citations, 2 randomized controlled trials (RCTs) and 3 retrospective cohorts with 717 patients receiving sugammadex and 812 patients receiving cholinesterase inhibitors were included. Significantly lower rates of prolonged postoperative ileus (OR .44, 95% CI .25-.77, P < .05, I2 = 56%, low certainty evidence) was observed with sugammadex. No significant difference in any other outcome was observed. Narrative review of readmission data demonstrated no significant difference.
CONCLUSION: The use of sugammadex following gastrointestinal surgery is associated with significantly lower rates of prolonged postoperative ileus compared to cholinesterase inhibitors. However, these do not translate into a significant reduction in length of stay, morbidity, or postoperative nausea and vomiting. Results are limited by the numer of studies included and missing data, more robust RCTs are needed before recommendations can be made.
Prophylactic and curative treatment of allergic disorders in cats, dogs, pigs, horses and cattle comprises administering a cpd. having activity similar to that of sodium cromoglycate, esp. one of formula (I) or one of their salts (where X is a 3-7C polymethylene chain opt. substd. by OH). Cpds. are used for the relief or prevention of respiratory and pulmonary disorders, neonatal diarrhoea in pigs and calves etc. Pref. dose is 40-80 mg daily by inhalation in calves and pigs. For gastrointestinal disorders the oral dose is preferably 10-200 mg for pigs and 50-500 mg for cattle. For cats and dogs the daily dose is 25-250 mg orally. In an example, epidemic diarrhoea in calves was prevented by treating 10 calves with 100 mg/day of disodium cromoglycate in 100 ml of milk from birth to day 21.
Placebo capsules were ordered to be prepared with the same color, taste and smell as the red cover capsules. Placebo capsules were administered orally twice a day with an interval of 12 hours for a total period of 6 months.
The present invention generally relates to compositions and methods for treatment of subjects having or at risk of cancer or other conditions. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
BACKGROUND Uterine dehiscence, an infrequent event often mistaken for uterine rupture, is rarely linked to post-cesarean section procedures and can result in severe complications, notably puerperal sepsis. In this report, we present a case that exemplifies the onset of puerperal sepsis and the emergence of intra-abdominal abscesses attributed to uterine dehiscence following a lower segment cesarean section (LSCS). CASE REPORT Our patient, a 28-year-old woman in her third pregnancy, underwent LSCS 1 week earlier. Subsequently, she returned to the hospital with lower abdominal pains, fever, and malodorous vaginal discharge. Computed tomography (CT) scan of whole abdomen verified uterine dehiscence and pus collection at the subhepatic region and right paracolic gutter. After referral to a specialized hospital, laboratory findings indicated an elevated white blood cell count and alkaline phosphatase levels, and coagulation abnormalities. She underwent an exploratory laparotomy, which unveiled uterine dehiscence, abscesses, and adhesions, necessitating a total abdominal hysterectomy and abdominal toileting. Pus culture analysis identified the presence of E. coli, which was susceptible to ampicillin/sulbactam. Complications were encountered after surgery, including wound dehiscence and pus re-accumulation. Successful management involved vacuum dressings and percutaneous drainage. Eventually, her condition improved and she was discharged, without additional complications. CONCLUSIONS This report underscores the importance of considering cesarean scar dehiscence as a diagnosis in women with previous cesarean deliveries who present during subsequent pregnancies with symptoms such as abdominal pain or abdominal sepsis. Diagnostic tools, such as CT, play pivotal roles, and the timely performance of an exploratory laparotomy is paramount when suspicion arises.
Patients at \<16 weeks will be assessed for risk factors for diabetes as described by ACOG. If patients meet criteria, they will be screened with two-step screening for gestational diabetes. If patients do not meet criteria, they will not be screened until the routine timing of screening for gestational diabetes.
Dapsone was not carcinogenic to rats when orally administered to females for 92 weeks or males for 100 weeks at dose levels up to 15 mg/kg/day (approximately 231 times the systemic exposure observed in humans as a result of use of the MRHD of dapsone gel, 5%, based on AUC comparisons). 

No evidence of potential to induce carcinogenesis was observed in a dermal study in which dapsone gel was topically applied to Tg.AC transgenic mice for approximately 26 weeks. Dapsone concentrations of 3%, 5%, and 10% were evaluated; 3% material was judged to be the maximum tolerated dosage. 

Dapsone was negative in a bacterial reverse mutation assay (Ames test), and was negative in a micronucleus assay conducted in mice. Dapsone was positive (clastogenic) in a chromosome aberration assay conducted with Chinese hamster ovary (CHO) cells. 

The effects of dapsone on fertility and general reproductive performance were assessed in male and female rats following oral dosing. Dapsone reduced sperm motility at dosages of 3 mg/kg/day or greater (approximately 15 times the systemic exposure that is associated with the MRHD of dapsone gel, 5%, based on AUC comparisons) when administered daily beginning 63 days prior to mating and continuing through the mating period. The mean numbers of embryo implantations and viable embryos were significantly reduced in untreated females mated with males that had been dosed at 12 mg/kg/day or greater (approximately 127 times the systemic exposure that is associated with the MRHD of dapsone gel, 5%, based on AUC comparisons), presumably due to reduced numbers or effectiveness of sperm, indicating impairment of fertility. When administered to female rats at a dosage of 75 mg/kg/day (approximately 956 times the systemic exposure that is associated with the MRHD of dapsone gel, 5%, based on AUC comparisons) for 15 days prior to mating and for 17 days thereafter, dapsone reduced the mean number of implantations, increased the mean early resorption rate, and reduced the mean litter size. These effects probably were secondary to maternal toxicity.
Group A will receive Pilates exercise with duration of 10-15 minutes and gradually progressing to 20-30 minutes. The session will hold 3 times per week over period of 8 weeks. It begins with warm-up and cool-down of about 5-10 minutes with rest interval of 1-2 minutes.
A smart flexible operating room lighting system with a control system utilizing artificial intelligence (AI) modules may be coupled to a wall, ceiling, or fixture of and mobile in a facility. The lighting system can modularly accommodate multiple illumination arms and incorporate microphones thereon, permitting the vocal control using the control system for hands free operations. The control system controls the movements of the illumination arms to desired positions and orientations via motor-driven actuators and position sensors thereon. The lighting system may include a speaker and a camera to facilitate two-way communications with a user via the control system to facilitate demonstrations for individuals undergoing tutelage in the facility. Further, a cover with a transparent front end may be provided to be slipped over the lighting system and securing through a cover fastener. Thus, the present invention provides reliable sanitary measures while facilitating efficient operations via the smart flexible illumination arms.
PROBLEM TO BE SOLVED: To prepare an aerosol type hair treatment composition, capable of being jetted from a nozzle of an aerosol container into a spray form and sticking in a formy form when reaching the hair, removing the foams at a moderate rate, good in compatibility with the hair and imparting the smoothness and softness to the hair. SOLUTION: This aerosol type hair treatment composition is a mixture of a stock solution containing (A) 0.5-5 pts.wt. higher alcohol, (B) 0.1-3 pts.wt. cationic surfactant and (C) 5-20 pts.wt. lower alcohol so as to provide 100 pts.wt. total amount thereof with a propellant comprising (i) a liquefied petroleum gas and (ii) dimethyl ether at a weight ratio (i)/(ii) within the range of (5/95) to (30/70). The weight ratio of (stock solution)/(propellant) is within the range of (60/40) to (90/10).
BACKGROUND Detection of episodes of desaturation on pulse oximetry in elderly people in community settings is now a common occurrence. Transfer of such patients to hospital by ambulance has led to a greatly increased exposure to high-dose (FiO₂ > 50%) inhaled oxygen therapy in this group. Current British Thoracic Society (BTS) guidelines recommend administration of oxygen, 15 L/min via a non-rebreather mask (NRB) to acutely hypoxemic patients with an SpO₂ below 85% on room air. In some elderly subjects, such high-dose oxygen therapy induces significant hypercapnia in the absence of an identifiable risk factor for oxygen-induced CO₂ retention. CASE REPORT This case series describes 3 very elderly (>85 years old) female patients developing acute hypercapnia shortly after initiation of high-dose inhaled oxygen therapy. In each of these cases, hypercapnia developed in the absence of an accepted risk factor for oxygen-induced CO₂ retention. In 2 cases, CO₂ narcosis resolved within hours of the establishment of controlled oxygen therapy on bi-level positive airway pressure (BPAP). The possibility of oxygen-induced CO2 retention was not considered by the treating physicians in the acute setting. CONCLUSIONS The possibility of oxygen-induced CO₂ retention should be considered in all elderly patients developing acute type II respiratory failure in the setting of high-dose oxygen therapy. Failure to recognize oxygen-induced CO₂ retention has significant implications for patient outcome and resource utilization.
The 4-step Coalition Check-Up technical assistance process provides proactive data-driven continuous quality improvement cycles. Step 1 assesses critical dimensions of the coalition's capacity and program implementation. A coalition profile based on assessment data is reviewed in step 2. Here the technical assistance provider works with the coalition to consider several dimensions of coalition capacity and program implementation, celebrating strengths and prioritizing weaknesses. Once priorities are set, the technical assistance provider uses structured action planning in step 3 to help coalition members establish consensus on how to improve prioritized weaknesses. In step 4, technical assistance providers review and support progress on action plan implementation with the coalition. Efforts are evaluated a year after the initial assessment in a continuous quality improvement cycle.
Participants received lubiprostone twice daily (BID). Participants received either lubiprostone 12 mcg BID, lubiprostone 24 mcg BID (dose based on participant's weight) up to 24 weeks.
Vasculitis associated with anti-neutrophil cytoplasm antibodies (ANCA) is a group of rare and severe autoimmune diseases, encompassing several entities: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (PMA), and eosinophilic granulomatosis with polyangiitis (GEPA). When untreated, these diseases are fatal in a matter of months. Currently, thanks to the use of corticosteroids and immunosuppressants, this high mortality has greatly decreased and these are now chronic diseases. On the other hand, these patients are at high risk of morbidity, linked to both relapses (occurring in at least 50% of patients) and side effects of treatments. It is therefore essential to be able to define which patients are at risk of relapse and justify long-term immunosuppressive treatment to avoid recurrence of the disease, and conversely which patients have a low risk of relapse and in whom immunosuppressive treatments can be discontinued to limit the risk of side effects. However, so far no predictor or biomarker can accurately assess this risk of relapse.
Obesity is one of the most alarming current health problems in the United States, with 31% percent of the population considered obese. Previous studies have shown that there is a higher incidence of depression in people who are overweight. It is not known whether depression causes obesity or vice versa, but the association may stem from the stigma of obesity or from the appetite and weight gain caused by depressive symptoms. With the increased risk of cardiovascular and other life-threatening diseases from obesity, promotion of healthful habits is important. Providing the motivational skills to adhere to these habits is also crucial, especially in people who are both overweight and depressed. This study will compare the effectiveness of two weight loss programs, one supplemented with health education and the other supplemented with behavioral counseling, in treating women who are depressed and overweight.

Participants in this 2-year study will be divided into one of two treatment groups: one group will address weight loss and depression via nutrition, exercise, and health education and the other group will address weight loss and depression via nutrition, exercise, and behavioral counseling. Participants receiving health education will learn about women's health topics and receive tips on staying healthy and preventing disease. Participants receiving behavioral counseling will learn about depression and links between activity and mood. They will also be asked to keep a diary of moods and activities. Participants in both treatment groups will undergo the same schedule of study visits and assessments. A baseline visit will include blood tests; measurements of height, weight, waist size, and blood pressure; and completion of questionnaires about depression, eating habits, and physical activity. Next, over a 3-week period, participants will receive three phone calls asking about food intake from the previous day. In the first 6 months of the study, there will be a total of 26 weekly treatment visits. These visits will consist of ten 1-hour sessions with a counselor and sixteen 90-minute sessions with a dietician. During the next 6 months, participants will continue to meet with their dieticians monthly for a total of 6 visits and will receive monthly phone calls from their counselor. Quaterly phone calls with their counselor will continue in the second year of the study. There will be three check-in appointments similar to the baseline assessment, occurring at Month 6 and Years 1 and 2.